Waseem Asghar, Ph.D., principal investigator and an associate professor in FAU’s Department of Electrical Engineering and Computer Science within the College of Engineering and Computer Science.
(Photo by Alex Dolce)
As of 2020, there were 37.7 million people globally living with HIV and 680,000 people died from AIDS-related illnesses last year. Since the start of the epidemic, more than 36.3 million people have died from AIDS-related illnesses.
Although antiretroviral therapy is effective in saving AIDS patients’ lives, implementing the therapy worldwide has been drastically hampered by the lack of treatment monitoring diagnostics and disease management. According to recent statistics by USAIDS, the coverage of antiretroviral therapy is still only 59 percent, despite being affordable or freely available in most countries. Moreover, worldwide, about 1 in 4 people who have contracted the virus are unaware of their HIV status.
With this grant, researchers are developing an affordable, disposable self-testing HIV-1 chip that can selectively detect HIV from whole blood samples, be highly sensitive to detect HIV during the acute infection, treatment and viral rebound; be rapid within 40 minutes; highly stable without requiring refrigeration; and fully automated providing true sample-in-answer-out ability.
“The greatest challenge to reducing HIV in developing countries that have limited resources is the absence of self-testing assays for viral load and the lack of trained technicians as well as modern laboratory infrastructure,” said Waseem Asghar, Ph.D., principal investigator and an associate professor in FAU’s Department of Electrical Engineering and Computer Science within the College of Engineering and Computer Science. “Currently, there is no reliable technology that can detect HIV during the early stages of the infection or measure viral rebound in antiretroviral therapy in treated patients in self-testing format.”
One of the fundamental challenges to reduce HIV burden and its prevalence is the absence of HIV self-testing assays that are sensitive enough to detect new HIV infections during the first two-weeks, which is the acute phase, post-infection and viral rebound in virally-suppressed patients receiving antiretroviral therapy. Current self-testing technologies only detect the host antibody response to HIV infection, which usually arises three to four weeks after the initial infection and it is not an indicator of therapy failure and viral rebound.
Asghar is developing this technology with co-investigator Massimo Caputi, Ph.D., a professor of biomedical science in FAU’s Schmidt College of Medicine, who has expertise in the molecular biology of HIV-1 and the mechanisms of regulating cellular and viral splicing. Caputi has made important contributions to the understanding of how cellular proteins modulate the replication of the HIV-1 genome.
The new technology employs an innovative microfluidic design integrated with molecular amplification that allows HIV testing without the need for skilled technicians to operate, making it suitable for self-testing format in developing countries as well as developed countries. The researchers plan to validate the functioning microchip with blood/plasma samples from more than 200 HIV-infected subjects.
“No molecular HIV self-testing technologies have yet been commercialized that are able to detect HIV during the early stages of acute infection or viral rebound in suppressed patients on antiretroviral therapy and there is an urgent need to develop reliable and affordable HIV self-testing technologies,” said Stella Batalama, Ph.D., dean, College of Engineering and Computer Science. “The technology that is being developed by professors Asghar and Caputi and our colleagues will be a game changer for helping to increase access to HIV testing and for improving treatment outcomes.”
Collaborators of the NIH grant include the University of Virginia and University of Pennsylvania.
